Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.72 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.72 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.72 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.72 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.72 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.72 |
| ▸ | ESR1 | P03372 | 3/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.61 |
| ▸ | ACHE | P22303 | 2/20 | 0.61 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kushenol N SCHEMBL564568 | 0.91 | BACE1 (0.73) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Kushenol N SCHEMBL30451391 | 0.91 | BACE1 (0.73) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Kushenol N SCHEMBL27013512 | 0.91 | BACE1 (0.73) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Kushenol N SCHEMBL27013513 | 0.91 | BACE1 (0.73) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Kushenol N SCHEMBL564366 | 0.91 | BACE1 (0.73) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| SCHEMBL27013445 | 0.88 | BACE1 (0.58) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| SCHEMBL564482 | 0.85 | BACE1 (0.57) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Sophoraflavanone G SCHEMBL15090973 | 0.84 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Sophoraflavanone G SCHEMBL904617 | 0.84 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H | |
| Sophoraflavanone G SCHEMBL17626648 | 0.84 | BACE1 (1.00) | BACE1SLC5A1SLC5A2CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294388-B1 | EXTRACTS FROM SOPHORA SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE | SCHWABE WILLMAR GMBH & CO (DE) | 2004-01-07 | — | — | EP | claimed |
| US-20030180394-A1 | Extracts from sophora species, method for producing the same and their use | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2003-09-25 | — | — | US | claimed |
| EP-1294388-A1 | EXTRACTS FROM i SOPHORA /i SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE | Dr. Willmar Schwabe GmbH & Co. (DE) | 2003-03-26 | — | — | EP | claimed |
| WO-2002000236-A1 | EXTRACTS FROM SOPHORA SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2002-01-03 | — | — | WO | claimed |
| CN-119314586-A | Screening method and application of gamma-secretase inhibitor | 沈阳医学院 | 2025-01-14 | — | — | CN | disclosed |
| CN-118501283-A | Quick fishing method for traditional Chinese medicine active components based on multi-target proteins | 云南中医药大学 | 2024-08-16 | — | — | CN | disclosed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11479537-B2 | T-type calcium channel inhibitor | KINKI UNIVERSITY (JP) | 2022-10-25 | — | — | US | disclosed |
| EP-3000465-B1 | T-TYPE CALCIUM CHANNEL INHIBITOR | UNIV KINKI (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20200308132-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2020-10-01 | — | — | US | disclosed |
| EP-1294389-B1 | THERAPEUTICAL USE OF SOPHORA FLAVESCENS OR SOPHORA SUBPROSTRATA EXTRACTS | SCHWABE WILLMAR GMBH & CO (DE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1294388-B1 | EXTRACTS FROM SOPHORA SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE | SCHWABE WILLMAR GMBH & CO (DE) | 2004-01-07 | — | — | EP | disclosed |
| US-20030190375-A1 | Therapeutical use of sophora flavescens or sophora subprostrata extracts | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030180394-A1 | Extracts from sophora species, method for producing the same and their use | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2003-09-25 | — | — | US | disclosed |
| EP-1294388-A1 | EXTRACTS FROM i SOPHORA /i SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE | Dr. Willmar Schwabe GmbH & Co. (DE) | 2003-03-26 | — | — | EP | disclosed |
| EP-1294389-A1 | THERAPEUTICAL USE OF i SOPHORA FLAVESCENS /i OR i SOPHORA SUBPROSTRATA /i EXTRACTS | Dr. Willmar Schwabe GmbH & Co. (DE) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000237-A1 | THERAPEUTICAL USE OF SOPHORA FLAVESCENS OR SOPHORA SUBPROSTRATA EXTRACTS | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000236-A1 | EXTRACTS FROM SOPHORA SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190375-A1 | Therapeutical use of sophora flavescens or sophora subprostrata extracts | SHBG, CYP19A1, HSD17B11 | BACE1 440/4885SLC5A1 172/4885SLC5A2 371/4885 |
| US-11479537-B2 | T-type calcium channel inhibitor | CACNA1H, CACNA1I, CACNA1G | BACE1 713/4885SLC5A1 355/4885SLC5A2 855/4885 |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | THPO, SERPINB1, SERPINC1 | BACE1 3298/4885SLC5A1 77/4885SLC5A2 256/4885 |
| US-20200308132-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1H, CACNA1I, CACNA1G | BACE1 713/4885SLC5A1 355/4885SLC5A2 855/4885 |
| US-20030180394-A1 | Extracts from sophora species, method for producing the same and their use | CYP19A1, SHBG, CYP17A1 | BACE1 192/4885SLC5A1 1089/4885SLC5A2 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.